Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study  by Nanas, John N et al.
Outcome of Patients With Congestive
Heart Failure Treated With Standard Versus
High Doses of Enalapril: A Multicenter Study
John N. Nanas, MD, PHD,* George Alexopoulos, MD,* Maria I. Anastasiou-Nana, MD,*
Konstantinos Karidis, MD,† Argiris Tirologos, MD,‡ Spyridon Zobolos, MD,i Vlasios Pirgakis, MD,§
Labros Anthopoulos, MD, PHD,# Dimitrios Sideris, MD, PHD,** Stamatis F. Stamatelopoulos, MD, PHD,*
Spyridon D. Moulopoulos, MD, PHD,* for the High Enalapril Dose Study Group
Athens, Greece
OBJECTIVES We sought to prospectively and randomly compare survival with clinical and hemodynamic
variables in patients with congestive heart failure (CHF) treated with standard versus high
doses of enalapril.
BACKGROUND Angiotensin-converting enzyme (ACE) inhibitors produce hemodynamic and symptomatic
benefits in patients with CHF, but there is still controversy about the optimal dose in this
clinical setting.
METHODS Two hundred and forty-eight patients with advanced CHF (age 56.3 6 12 years) were
randomized to receive a maximal tolerated dose of enalapril, up to 20 mg/day in group 1
(mean dose achieved 17.9 6 4.3 mg/day, n 5 122) and 60 mg/day in group 2 (mean dose
achieved 42 6 19.3 mg/day, n 5 126).
RESULTS At enrollment, patients in group 1 were in New York Heart Association (NYHA) functional
class 2.6 6 0.7 and had a mean systolic blood pressure (SBP) of 117 6 18 mm Hg, a mean
heart rate (HR) of 85 6 16 beats/min and a left ventricular ejection fraction (LVEF) of
20.0 6 9.8%. In group 2, patients were in NYHA class 2.6 6 0.7; their SBP was 118 6
17 mm Hg, HR 83 6 15 beats/min and LVEF 18.8 6 8.1%. There were no significant
differences in these characteristics between the two groups of patients at enrollment. After 12
months of follow-up, 22 (18%) of 122 patients in group 1 and 23 (18%) of 126 patients in
group 2 had died (p 5 0.995, with 80% power of the study to detect a delta difference of 13%).
The NYHA class was the same (1.9 6 0.7) in both groups; SBP was 111 6 16 and 111 6
17 mm Hg, HR 77 6 12 and 79 6 13 beats/min and LVEF 31 6 19% and 30 6 12% in
groups 1 and 2, respectively. These differences were not statistically significant. The study had
a power of 80% to detect (p 5 0.05) the following changes: 13% in death rate, 0.25 units in
NYHA class, 6 mm Hg in SBP, 5 beats/min in HR and 6% in LVEF.
CONCLUSIONS No significant differences were found in survival and clinical and hemodynamic variables
between patients receiving standard and those receiving high doses of enalapril. (J Am Coll
Cardiol 2000;36:2090–5) © 2000 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors produce
hemodynamic and symptomatic benefits in patients with
congestive heart failure (CHF) beyond those which can be
achieved with conventional drugs (1–6). The COoperative
North Scandinavian ENalapril SUrvival Study (CONSEN-
SUS) (7) and Studies Of Left Ventricular Dysfunction
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(SOLVD) (8) have shown that enalapril significantly re-
duces mortality in patients with CHF. An overview of the
randomized trials examining the effect of ACE inhibitors on
mortality and morbidity in patients with heart failure
identified 34 completed trials of ACE inhibitors compared
with placebo (9). A meta-analysis of these data showed that
ACE inhibitors significantly reduce total mortality and
hospital stays due to CHF decompensation, with consistent
effects in a broad range of patients. The beneficial effect of
ACE inhibitors appears to be a class effect. However, nearly
half of the patients included in these 34 studies were treated
with enalapril.
In the large enalapril trials (7,8,10,11)—CONSENSUS,
SOLVD (Treatment), SOLVD (Prevention) and Veterans
Administration Vasodilator Heart Failure Trial (V-Heft
II)—the final mean dose of enalapril was 15 to 18.4 mg/day;
the intended dose was 40 mg/day for CONSENSUS and
20 mg/day for the other trials. Small-scale studies have
shown that large doses of ACE inhibitors produce greater
hemodynamic (12,13) and clinical improvement (14–16)
compared with customary doses.
This trial was designed to evaluate the effects of high dose
enalapril compared with standard dose enalapril on the
mortality, morbidity and clinical status of patients with
CHF.
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METHODS
This was a prospective, randomized trial that was open-label
for the treatment and functional status evaluation and
blinded for the laboratory evaluation of patients with mod-
erate to severe CHF.
All patients in the study had symptoms of heart failure for
at least three months and had left ventricular ejection
fractions (LVEFs) #0.35. Patients were randomized to
receive the maximal tolerated dose of enalapril, up to
20 mg/day (10 mg twice daily) in group 1 and up to
60 mg/day (30 mg twice daily) in group 2. All patients in
the trial initially received standard therapy with digoxin,
nitrates and diuretics, as needed. Treatment was started on
an outpatient basis, at a dose of 2.5 mg twice daily. The
dosage of enalapril was titrated at weekly intervals and
reached the target dose on the fifth week in group 1
(20 mg/day) and on the ninth week in group 2 (60 mg/day).
Enalapril was not increased further if the systolic blood
pressure (SBP) dropped to ,90 mm Hg or if the drug
induced symptoms of hypotension. The patients were clin-
ically evaluated every week until enalapril dose maximiza-
tion and on the third, sixth and twelfth month of follow-up
thereafter.
In addition, all patients underwent a blinded evaluation
of their left ventricular function by radionuclide ventricu-
lography before randomization and at one-year follow-up.
Patients were excluded if any of the following was present:
acute pulmonary edema within the previous 15 days, hemo-
dynamically important aortic or mitral valve stenosis, myo-
cardial infarction or open heart surgery within the previous
three months, unstable angina, anticipated cardiac surgery,
right heart failure due to pulmonary disease, serum creati-
nine concentration .3 mg/dl, hypertrophic or restrictive
cardiomyopathy or pericardial disease. The principal end
points of the trial were the one-year mortality rate and cause
of death. Sudden death was defined as death within 1 h of
the onset of new symptoms (17). In addition, the major
secondary objective was the evaluation of the effect of high
dose enalapril on cardiovascular morbidity, defined as hos-
pital admission for heart failure or other cardiovascular
causes, and on the patients’ clinical status and left ventric-
ular function.
The study was approved by the hospitals’ Review Com-
mittees, and informed consent was obtained from each
patient.
Statistical analysis. The power of the study was estimated
for the 248 recruited patients. This sample size provides the
ability to detect, with a power of 80% and p 5 0.05, the
following changes: 13% in death rate, 0.25 units in New
York Heart Association (NYHA) functional class,
6 mm Hg in SBP, 5 beats/min in heart rate (HR) and 6%
in LVEF. These are relatively small changes for each clinical
variable.
The baseline characteristics of the two treatment groups
were compared by using the t test and the chi-square test.
Cumulative survival curves were constructed as time to first
event plots by Kaplan-Meier survivorship methods, and the
differences between the curves were tested for significance
by the log-rank statistics, with the use of the Cox propor-
tional hazards regression model (which included the proto-
col and other variables as covariates), for the determination
of hazard ratios. For continuous variables, the median value
was used as a cut-off level. The analyses included all
randomized patients, and all events were assigned to the
patients’ original treatment group (on the intention-to-treat
principle). In the analysis of mortality, patients were cen-
sored at the time of death or cardiac transplantation.
Changes over time in clinical status (NYHA), ejection
fraction, blood pressure and HR were analyzed by the paired
t test. The unpaired t test was used for comparisons between
the two groups. All data are presented as the mean value 6
SD.
RESULTS
Recruitment of patients began in July 1993 and ended in
December 1997. Patients were enrolled in the trial and
randomly assigned to the standard target dose of enalapril,
10 mg twice daily (group 1, n 5 122), or to the high target
dose of enalapril, 30 mg twice daily (group 2, n 5 126).
No patient was lost in follow-up. The baseline charac-
teristics of the randomized patients in group 1 (n 5 122)
and in group 2 (n 5 126) were similar (Table 1).
Although LVEF #35% was sufficient to qualify for entry
into the study, the mean ejection fraction of the patients in
this study was very low—20.0 6 9.8% in group 1 and
18.8 6 8.1% in group 2 (p 5 0.424). The dose titration of
enalapril reached a mean total daily dose of 17.9 6 4.4 mg
for group 1 and 42.5 6 19.4 mg for group 2 (p 5 0.000). In
groups 1 and 2, respectively, 72.5% and 32.5% of the
patients reached their target enalapril doses by the end of
three months of follow-up, and 79.6% and 45.5%, respec-
tively, by the end of the first year.
Concomitant therapy. There were no differences between
the two groups with respect to concomitant treatment
during the follow-up period. At the end of the study, 95%
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ATLAS 5 Assessment of Treatment with
Lisinopril And Survival study
CHF 5 congestive heart failure
CONSENSUS 5 COoperative North Scandinavian
ENalapril SUrvival Study
HR 5 heart rate
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
SBP 5 systolic blood pressure
SOLVD 5 Studies Of Left Ventricular
Dysfunction
V-HeFT 5 Veterans Administration Vasodilator
Heart Failure Trial
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of the patients in group 1 were treated with digoxin (mean
dose 0.197 6 0.0646 mg/day) versus 90% of the patients in
group 2 (mean dose 0.199 6 0.068 mg/day) (p 5 0.849).
All patients were treated with furosemide (105.98 6
97.00 and 115.47 6 123.00 mg/day in groups 1 and 2,
respectively) (p 5 0.655).
Effect of different enalapril dosages on survival. By
intention-to-treat analysis, there were 22 deaths (18.03%) in
group 1 and 23 deaths (18.25%) in group 2 (p 5 0.995)
(Fig. 1). When the protocol (high vs. standard dose) was
used as a covariate in the Cox regression model, with death
at one year as an end point, the hazards ratio was 0.998
(confidence interval [CI] 0.556 to 1.790).
No statistically significant differences in survival were
observed in subgroup analyses in terms of age, etiology of
heart failure, SBP, ejection fraction and HR when using
high dose enalapril as a covariant for each subgroup (Table
2).
A stratified analysis was also performed within each study
group to assess the potential different effects of the treat-
ment on patient subgroups (Tables 3,4).
In group 1, cause of heart failure, SBP and LVEF
appeared to have no prognostic significance. In contrast, in
group 2, ischemic cardiomyopathy, SBP ,120 mm Hg and
LVEF ,19% were predictors of poor prognosis, with
hazards ratios of 2.92 (CI 1.13 to 7.53, p 5 0.026), 2.99 (CI
1.16 to 7.72, p 5 0.023) and 4.09 (CI 1.37 to 12.19, p 5
0.012), respectively.
Data from the patients’ hospital admissions in both study
groups are summarized in Table 5. No statistically signifi-
Figure 1. Cumulative mortality in groups 1 and 2.
Table 1. Baseline Characteristics of the Treatment Groups
Group 1 (Standard Dose) Group 2 (High Dose) p Value
Age in years (range) 55.5 6 13.8 (18–75) 56.8 6 11.5 (21–76) NS
Male Gender (%) 89.6 80.6 NS
Duration of symptoms (months) 20.7 6 19.0 27.6 6 25.5 0.013
NYHA class (enrollment)(%)
II 41.5 42.6 NS
III 47.2 41.7 NS
IV 11.3 10.2 NS
CAD (%) 52.8 46.3 NS
IDC (%) 42.5 46.3 NS
Other cause 4.7 7.4 NS
Serum sodium (mEq/liter) 141.1 6 4.9 (125–152) 142.1 6 3.7 (132–150) NS
Creatinine (mg/dl) 1.1 6 0.3 (0.5–2.4) 1.2 6 0.4 (0.5–2.6) NS
Bilirubin (mg/dl) 1.1 6 0.7 (0.4–4.9) 1.05 6 0.8 (0.3–7.0) NS
Systolic BP (mm Hg) 116.8 6 18.2 117.6 6 17.3 NS
Heart rate (beats/min) 85.2 6 16.3 83.5 6 15.4 NS
LVEF (%) 20.0 6 9.8 18.8 6 8.1 NS
Data are presented as the mean value 6 SD or percentage of patients.
BP 5 blood pressure; CAD 5 coronary artery disease; IDC 5 idiopathic dilated cardiomyopathy; LVEF 5 left ventricular
ejection fraction; NS 5 not significant; NYHA 5 New York Heart Association.
Table 2. Effect of the Two Enalapril Dose Regimens on
Mortality in Patient Subgroups
Variable
Hazard
Ratio
Confidence
Interval p Value
Age ,57 years 0.81 0.35–1.89 0.638
Age $57 years 1.10 0.47–2.60 0.819
Heart rate ,80 beats/min 0.89 0.33–2.39 0.827
Heart rate $80 beats/min 1.23 0.56–2.69 0.607
Ischemic cardiomyopathy 1.20 0.58–2.48 0.624
Other cause of heart failure 0.71 0.25–2.07 0.538
NYHA class I and II 1.18 0.31–4.39 0.806
NYHA class III and IV 0.96 0.49–1.88 0.908
Systolic blood pressure
,120 mm Hg
1.44 0.66–3.13 0.358
Systolic blood pressure
$120 mm Hg
0.54 0.20–1.47 0.229
Male gender 1.09 0.58–2.02 0.788
Female gender 0.73 0.12–4.38 0.731
Ejection fraction ,19% 1.42 0.65–3.11 0.378
Ejection fraction $19% 0.56 0.16–1.91 0.353
Hazard ratios were determined with a Cox regression model, with the high dose
entered as a covariant. For continuous variables, the median value was used as a cutoff
level.
NYHA 5 New York Heart Association.
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cant differences were found. In addition, no difference was
found when death and hospital admission were used as a
composite end point for statistical analysis (p 5 0.645,
log-rank test) (Fig. 2).
At the 12-month evaluation, LVEF had increased from
20.0 6 9.8% to 31.5 6 19.2% (p 5 0.000) in group 1 and
from 18.8 6 8.1% to 30.1 6 12.3% (p 5 0.000) in group 2.
The patients’ functional status (NYHA) improved from
2.6 6 0.7 to 1.9 6 0.7 (p 5 0.000) in group 1 and from
2.6 6 0.7 to 1.9 6 0.7 (p 5 0.000) in group 2. However,
SBP and HR did not change significantly from baseline
levels in either group.
There was no significant difference in LVEF and NYHA
functional class between groups 1 and 2 at baseline and at
one-year follow-up. Furthermore, no significant difference
in the percent change in LVEF (p 5 0.535) and NYHA
class (p 5 0.329) was observed between the groups at
baseline and at one year. This study had more than adequate
power to detect clinically significant changes in the major
relevant variables (death rate, NYHA class, blood pressure,
HR and LVEF).
DISCUSSION
In this prospective, randomized study, the effects of high
dose enalapril on mortality and morbidity were compared
with those of standard dose enalapril. Both dosages im-
proved the patients’ clinical condition over the first three
months of treatment, without further significant improve-
ment during the rest of the follow-up period. There were no
differences in mortality or morbidity between the two
groups.
Our data showed a difference in the prognostic signifi-
cance of the etiology of heart failure (ischemic vs. other),
SBP (,120 vs. $120) and ejection fraction (,19% vs.
$19%) between the two study groups. The significance of
this observation remains to be established. It may be due to
a deleterious effect of high dose enalapril in patients with
ischemic cardiomyopathy, or to a salutary effect in patients
with dilated cardiomyopathy. No similar observations have
been made in previous large-scale trials of ACE inhibitors
(8,18,19), although conflicting results have been reported
with regard to the relative effectiveness of ACE inhibitors in
ischemic versus nonischemic heart disease (20,21).
In the three large survival studies—CONSENSUS (7),
SOLVD (8) and V-HeFT II (11)—enalapril was adminis-
Figure 2. Cumulative incidence of composite end point of mortality and
hospital admission in the two treatment groups.
Table 3. Prognostic Significance of Different Patient
Characteristics in Group 1
Variable
Hazard
Ratio
Confidence
Interval
p
Value
Age ,57 years 0.77 0.33–1.78 0.542
Male Gender 1.15 0.27–4.92 0.849
Systolic blood pressure
,120 mm Hg
1.13 0.49–2.62 0.766
Heart rate ($80 beats/min) 0.52 0.21–1.32 0.170
Cause of heart failure
(ischemic vs. other)
1.71 0.72–4.08 0.224
NYHA class III and IV
vs. class I and II
3.6 1.25–10.90 0.018
Ejection fraction ,20% 1.93 0.70–5.28 0.199
Continuous variables were treated the same as categoric variables, with the median
value as a cut-off level.
NYHA 5 New York Heart Association.
Table 4. Prognostic Significance of Different Patient
Characteristics in Group 2
Variable
Hazard
Ratio
Confidence
Interval
p
Value
Age ,57 years 1.05 0.45–2.48 0.904
Male gender 1.77 0.52–5.96 0.355
Systolic blood pressure
,118 mm Hg
2.99 1.16–7.72 0.023
Heart rate $80 beats/min 1.03 0.42–2.48 0.951
Cause of heart failure
(ischemic vs. other)
2.92 1.13–7.53 0.026
NYHA class III and
IV vs. class I and II
3.02 1.10–8.24 0.031
Ejection fraction ,19% 4.09 1.37–12.19 0.012
Continuous variables were treated the same as categoric variables, with the median
value as a cut-off level.
NYHA 5 New York Heart Association.
Table 5. One-Year Morbidity (Hospital Admissions) in the
Two Study Groups
Group 1 Group 2 p Value
Hospital admissions (n) 32 28 0.556
Hospital period (days) 434 419 0.573
Arrhythmia (n) 8 4 0.345
Heart failure decompensation (n) 17 19 0.940
Angina (n) 3 4 0.999
Noncardiogenic causes (n) 4 1 0.208
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tered in mean doses of 18.4, 16.6 and 15 mg/day, respec-
tively. In the first study, the target dose was 40 mg/day, and
in the other two trials, the target dose was 20 mg/day. These
studies have shown that enalapril can alter the natural
history of heart failure and significantly improve these
patients’ long-term prognosis.
Dose response trials of ACE inhibitors. The results of
the Assessment of Treatment with Lisinopril And Survival
(ATLAS) trial, a large-scale clinical study comparing two
different doses of lisinopril in patients with CHF, have
recently been reported (22). The high dose group had a
nonsignificant 8% lower risk of death (p 5 0.128), but a
significant 12% lower risk of death or hospital admission for
any reason (p 5 0.002). However, there were major differ-
ences between the ATLAS trial and ours. First, the low
dose group received a very low dose of lisinopril (2.5 to
5 mg/day). Second, the high dose group received doses
comparable to those of our standard dose group (group 1)
and to those used in the clinical trials that demonstrated a
reduction in morbidity and mortality (7,8).
In addition, the results of another large, multicenter,
randomized clinical trial—the NETWORK of general
practitioners and hospital physicians involved in the study of
low versus high doses of enalapril in patients with heart
failure—which compared the effect of low versus high doses
of enalapril on mortality in patients with CHF, were
recently reported. There were no differences between the
three different regimens tested, neither in the combined end
point (death, hospital admission and worsening of heart
failure) nor in mortality alone, at the completion of six
months follow-up. The results of this study are not com-
parable to ours, mainly because the doses of enalapril, in all
three groups of the trial, were lower (2.5 mg 3 2, 5 mg 3
2 and 10 mg 3 2), whereas in our study, the effect of a
substantially larger dose (30 mg 3 2) was compared with
that of the usual dose (10 mg 3 2), which was identical to
the higher dose used in NETWORK. In addition, in the
NETWORK trial, patients with less severe heart failure
were enrolled (65% in NYHA class II and 35% in NYHA
class III), and the follow-up period was shorter (six
months). This might explain the low mortality rate observed
in the study in question (23).
Enalapril trials. The mean achieved enalapril dose of
17.9 mg/day in our standard dose group was comparable to
that achieved in CONSENSUS (18.4 mg/day), SOLVD
(16.6 mg/day) and V-HeFT II (15 mg/day). To the best of
our knowledge, ours is the first comparative study of
enalapril, using the standard dose of the large survival trials
(7–10) as low dose, and as high dose, a target of 60 mg/day,
resulting in an actually administered mean dose of 42.5 mg,
the highest ever reported.
The higher overall mortality (18.1%) in our study, in
comparison to 12.4% in SOLVD and 9.0% in V-HeFT II,
may be explained by the lower mean LVEF of our patients
(19.4% in our study vs. 24.8% in SOLVD vs. 28.6% in
V-HeFT II), the lower mean SBP (117.2 mm Hg in our
study vs. 125.3 mm Hg in SOLVD vs. 125.5 mm Hg in
V-HeFT II) and the lower NYHA functional class (10.7%
for patients in class IV in our study vs. 1.5% in SOLVD vs.
2% in V-HeFT II). In contrast, the mortality rate in our
study was lower than that observed in the CONSENSUS
study (36%), most likely because the patients included in
that study were in worse overall clinical conditions (10.7%
for patients in class IV in our study vs. 100% in CONSEN-
SUS), and because relatively fewer patients had coronary
artery disease in our study (50.2%) than in CONSENSUS
(72%). Measurements of LVEF were not reported in
CONSENSUS.
The relatively low mortality rate in our study, despite the
severely depressed LVEF, poor clinical status and low SBP,
may be attributable not only to enalapril treatment, but also
to overall advances in the treatment of cardiovascular
diseases made in the last decade, offering a comprehensive
management of advanced heart failure (24).
Clinical significance. The results of our study and previous
experimental data (25–27) suggest that inhibition of circu-
lating ACE to reduce plasma angiotensin II is probably not
the sole important action of ACE inhibitors. This hypoth-
esis is supported by small clinical studies that have shown
that high doses of ACE inhibitors produce hemodynamic
effects comparable to those of low doses (1,16,28–30).
On the basis of the findings of our study and previous
comparative studies (16), as well as large survival trials (7–9)
of enalapril, the dose of 20 mg/day seems to be optimal to
improve hemodynamic and clinical status, and probably for
life prolongation in patients with CHF. Data are insufficient
to assess the effect of lower doses than the ones used in the
large survival trials (31–33).
Study limitations. The present study was not blinded with
regard to the patients’ treatment. Therefore, a bias of
physicians and patients in favor of the standard dosage
cannot be excluded, because high doses may produce more
side effects. However, the significant difference in the
achieved doses between groups 1 and 2 argues against this
bias. In addition, the study was blinded with regard to the
laboratory evaluations. Regarding a stratified survival anal-
ysis, the number of patients in each subgroup was too small
for valid comparisons.
Conclusions. Doses of enalapril higher than those used in
the large clinical trials of ACE inhibitors as treatment for
patients with CHF do not appear to improve the survival of
these patients. However, larger scale trials may be warranted
to determine whether selected patient subgroups might
benefit from higher doses.
APPENDIX
The following centers and investigators collaborated in this
study (values in parentheses denote the number of patient
enrolled).
University of Athens, Department of Clinical Thera-
peutics, Alexandra Hospital, Athens (n 5 178): D.
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Kontoyannis, S. Rokas, S. Nanas, S. Toumanidis, J. Ka-
nakakis, S. Gerali, Z. Margari, A. Rapti, N. Kouvelas, J.
Terrovitis, E. Tsolakis, K. Christodoulou, L. Palazis, A.
Kalampalikis, G. Kanelos, A. Mosxona, D. Kostantonis, G.
Panagoulias, E. Tsagalou, A. Eleftheriou, J. Stathopoulos, J.
Scotiniotis, S. Drakos, A. Dalianis, C. Batziou, D. Alexan-
dropoulos, D. Zervakis, K. Moussoutzani, P. Kaiafas, E.
Patsi, E. Zafiris, K. Makaritsis, M. Margari; Kavala Gen-
eral Hospital, Kavala (n 5 19): D. Simeonidis, P.
Dougleris, N. Papoulidis; Sotiria General Hospital, Ath-
ens (n 5 18): S. Limperi, S. Georgiadis, S. Kakouros;
Kalamata General Hospital, Kalamata (n 5 13): G.
Asimakis, G. Koudounis; Ioannina University Hospital,
Ioannina (n 5 9): A. Achenbach; Korinthos General
Hospital, Korinthos (n 5 8) O. Kapi-Liata; Evangelismos
Hospital, First Cardiology Clinic, Athens (n 5 3): K.
Bouki.
Reprint requests and correspondence: Dr. John N. Nanas,
Makedonias 24, GR 104 33 Athens, Greece.
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